MULTIGEN
LIVE

Serial Number

79404951

Owner

Confo Therapeutics NV

Attorney

Jessica S. Sachs

Filing Date

Jul 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MULTIGEN Trademark

Serial Number: 79404951

MULTIGEN is a trademark filed by Confo Therapeutics NV on July 9, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Confo Therapeutics NV

Technologiepark 30

Entity Type: 99

Confo Therapeutics N.V. (10 trademarks)

Technologiepark,

Entity Type: 98

Trademark Details

Filing Date

July 9, 2024

Registration Date

Not Registered

Published for Opposition

February 3, 2026

Goods & Services

Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs); none of the foregoing for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies

Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management; none of the foregoing services for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies

chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteins, namely, small molecules and antibodies for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; veterinary products, namely, antigens and reagents for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; none of the foregoing for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies

Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines; none of the foregoing services for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 3, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 3, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Jan 29, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 28, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 14, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 13, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 5, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 5, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 5, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 27, 2025 GNFN
FINAL REFUSAL E-MAILED
Oct 27, 2025 GNFR
FINAL REFUSAL WRITTEN
Oct 27, 2025 CNFR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Aug 12, 2025 CORR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2025 TROA
REFUSAL PROCESSED BY IB
Feb 22, 2025 RFNT
CORRECTION TRANSACTION RECEIVED FROM IB
Feb 14, 2025 CRCV
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 6, 2025 RFCS
REFUSAL PROCESSED BY MPU
Feb 6, 2025 RFRR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jan 31, 2025 ADCH
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 1, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 31, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 30, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 27, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 27, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 26, 2024 REPR